MedTrace Logo

Research of Circulating Tumor Cells Released During Cervical Cancer Surgery

NCT04770090 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-07-10

No results posted yet for this study

Summary

Cervical cancer is a rare pathology. Recent studies showed that the risk of recurrence is higher for patients treated by coelioscopy in comparison with laparotomy. It could be explained by the spread of circulating tumor cells (CTC) due to tumor mobilization during different steps of the surgery.

The primary goal is to evaluate the spread of CTC during surgery on peripheral blood samples.

The secondary outcome is to evaluation the disease-free survival at 3 and 5 years postoperatively.

20 patients with early stage cervical (IA1 to IB2) eligible to coelioscopic stadification and laparoscopic surgery will be included.

Conditions

  • Cervical Cancer Stage IA1
  • Cervical Cancer Stage IB1
  • Cervical Cancer Stage IA2
  • Cervical Cancer Stage IB2

Interventions

OTHER

Blood samples

Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    collaborator OTHER

  • Institut du Cancer de Montpellier - Val d'Aurelle

    collaborator OTHER

  • Laboratoire Cellules Circulantes Rares Humaines

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2022-08-22
Completion
2022-08-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770090 on ClinicalTrials.gov